Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"
Condition(s) studied
Investigational drug(s) / intervention(s)
Insulin + semaglutide treatment: Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)
Usual insulin treatment: Usual insulin treatment
Biological check-up: at D0, D90 and D180
Study summary
Between 16% and 22% of type 1 diabetic patients present a clinical and biological profile of insulin resistance favored by a family history of type 2 diabetes or metabolic syndrome. They constitute a group of patients with "double diabetes" since they have both true type 1 diabetes and inherited insulin resistance, typical of type 2 diabetes.
For several years, GLP1 agonists have been successfully used in the treatment of type 2 diabetes, leading to very significant improvements in glycemic control and weight loss.
Because of the insulin-sensitizing power of GLP1 agonists, the investigators hypothesize that they could reduce insulin resistance in patients with "double diabetes" and thus improve their glycemic control.
The investigators propose to use in this study semaglutide, the most recent and most potent GLP1 agonist (superiority demonstrated compared to exenatide LP and dulaglutide) and administered as a weekly subcutaneous injection (in contrast to liraglutide administered daily).
Eligibility
Primary outcome measure(s)
- Percentage of time spent within glycemic target range (0.70-1.80 g/l) — Change from baseline at Day 180
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Chu Dijon Bourgogne | Dijon | France | Recruiting |
More Centre Hospitalier Universitaire Dijon trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05305794 on ClinicalTrials.gov ↗ ← All trials in France